Observational studyJournal of cosmetic dermatology2025
Real-World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add-On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study.
Observational study in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogenetic alopecia (AGA) is a common age-related hair loss condition influenced by genetics and androgen activity.
aimThis study evaluated the safety and efficacy of Cuticapil Stem Hair Serum in improving hair loss in AGA patients.
methodThis multicenter, prospective, observational study assessed the real-world efficacy and safety of Cuticapil Stem Hair Serum in patients with androgenetic alopecia. A total of 60 subjects were evaluated, with the Cuticapil and Standard of Care groups compared using the Mann-Whitney and Wilcoxon signed-rank tests. Key assessments included the hair pull test, global photographic analysis, and hair shedding count. No adverse events were reported, reinforcing the serum's favorable safety profile.
resultThe Cuticapil + SoC treatment group consistently showed higher mean ranks across multiple parameters compared to the SoC-only group. The addition of Cuticapil Serum to SoC significantly reduced hair shedding (p = 0.0220). In the Hair Pull Test, the Cuticapil + SoC group had a lower mean rank (26.97) than SoC alone (34.03) (p = 0.0196), indicating greater efficacy. Global photography analysis showed a higher mean rank of 36.13 in the Cuticapil + SoC group compared to 24.87 in the SoC group (p = 0.0057), further supporting its effectiveness.
conclusionCuticapil Stem Hair Serum, when used in addition to standard care, significantly enhances hair growth and reduces hair fall in patients with mild to moderate Androgenetic Alopecia and Female Pattern Hair Loss. It showed superior results in promoting hair growth, reducing shedding, improving hair density, appearance, and managing hair loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.